Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | 88901-36-4 | HCID 24721270 | — |
| Reactant | [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1R,4S,5R,9S,10R,13S)-13-[(2S,3R,4S,5S,6R)-3-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate | HCID 44564215 | — |
| Solvent | Water | HCID 962 | — |
| Product | Sucrose | HCID 5988 | 5% |
Reaction Steps
Rebaudioside A and mogroside V were mixed in the same manner as in Example 1 with the compounding ratio (weight ratio) shown in Table 3. Water was added to the mixture so as to obtain a degree of sweetness (intensity of sweetness) similar to that of a 5% aqueous sucrose solution, and eight types of aqueous solutions containing rebaudioside A and/or mogroside V were prepared. Among these aqueous test solutions, thaumatin was added to each aqueous solution, except for an aqueous solution consisting of 100 parts by mass of rebaudioside A (Control, rebaudioside A:mogroside V=100:0), so that its concentration became 1 ppm. The pH of each aqueous solution was adjusted to 3 and 4.5 using citric acid and trisodium citrate, and to 7 using sodium bicarbonate.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US09044038B2 |
|---|
| Source dataset | uspto-grants-2015_06 |
|---|
| ORD ID | ord-fd4168d9ad2244ffa4f9e4b39595b2c8 |
|---|
| Source note | uspto-grants-2015_06 |
|---|
